Status:
COMPLETED
Raloxifene Use for The Heart
Lead Sponsor:
Eli Lilly and Company
Conditions:
Cardiovascular Diseases
Breast Neoplasms
Eligibility:
FEMALE
55+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for...
Eligibility Criteria
Inclusion
- Postmenopausal women with established coronary heart disease or at risk for a major coronary event.
Exclusion
- Postmenopausal symptoms that required estrogen replacement therapy.
- Suspected or known history of breast or endometrial carcinoma.
- Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis.
- New York Heart Association classes III or IV heart failure.
Key Trial Info
Start Date :
June 1 1998
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT00190593
Start Date
June 1 1998
End Date
November 1 2005
Last Update
January 26 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Minneapolis, Minnesota, United States